Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101

Phase 2/3Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myasthenia Gravis

Conditions

Myasthenia Gravis, Generalized Myasthenia Gravis

Trial Timeline

Aug 28, 2024 → Sep 1, 2028

NCT ID

NCT06193889

About Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101

Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101 is a phase 2/3 stage product being developed by Kyverna Therapeutics for Myasthenia Gravis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06193889. Target conditions include Myasthenia Gravis, Generalized Myasthenia Gravis.

What happened to similar drugs?

1 of 20 similar drugs in Myasthenia Gravis were approved

Approved (1) Terminated (2) Active (17)

❌SatralizumabChugai PharmaceuticalPhase 3

🔄tacrolimusAstellas PharmaPhase 3

🔄Tacrolimus capsule + PlaceboAstellas PharmaPhase 3

🔄tacrolimus + placeboAstellas PharmaPhase 3

🔄Cladribine Low Dose + Cladribine High DoseMerckPhase 3

🔄Remibrutinib (Blinded) + Remibrutinib (Open Label)NovartisPhase 3

🔄IptacopanNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06193889	Phase 2/3	Recruiting	Aug 28, 2024	Sep 1, 2028	Myasthenia Gravis

Competing Products

20 competing products in Myasthenia Gravis

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	32
tacrolimus	Astellas Pharma	Phase 3	40
Tacrolimus capsule + Placebo	Astellas Pharma	Phase 3	40
tacrolimus + placebo	Astellas Pharma	Phase 3	40
Ravulizumab	AstraZeneca	Pre-clinical	33
Cladribine Low Dose + Cladribine High Dose	Merck	Phase 3	47
Remibrutinib (Blinded) + Remibrutinib (Open Label)	Novartis	Phase 3	47
Placebo + CFZ533	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	47
mycophenolate mofetil [CellCept] + Placebo	Roche	Phase 3	40
mycophenolate mofetil (CellCept) + placebo	Roche	Phase 3	40
inebilizumab + IV Placebo	Amgen	Phase 3	44
Inebilizumab	Amgen	Phase 2	42
Abatacept Injection	Bristol Myers Squibb	Phase 1	21
Tolebrutininb + Placebo	Sanofi	Phase 3	32
Pozelimab + Cemdisiran + Cemdisiran + Pozelimab	Regeneron Pharmaceuticals	Phase 3	44
HIZENTRA ®	CSL	Phase 2	35
Subcutaneous immunoglobulins	CSL	Phase 1	21
Human normal immunoglobulin G (IgG)	CSL	Phase 3	40
zilucoplan (RA101495)	UCB	Phase 3	44